1. |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
|
2. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
3. |
万赤丹, 王国斌. 原发性肝癌治疗进展. 腹部外科, 2019, 32(1): 1-6, 22.
|
4. |
王春平, 任波, 陆荫英, 等. 原发性肝癌诊疗规范(2017年版)更新解读. 传染病信息, 2017, 30(4): 193-196, 202.
|
5. |
曲建慧, 张翠红, 李若然, 等. 肝细胞癌免疫治疗的现状与挑战. 传染病信息, 2016, 29(4): 193-197, 208.
|
6. |
郭静, 曲鑫建, 伍会健. 肿瘤免疫疗法中免疫检查点的研究进展. 生理科学进展, 2017, 48(4): 287-293.
|
7. |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264.
|
8. |
Bachy E, Coiffier B. Anti-PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncol, 2014, 15(1): 7-8.
|
9. |
Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol, 2014, 15(1): 137-146.
|
10. |
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J, 1992, 11(11): 3887-3895.
|
11. |
郭国宁, 谢谆怡, 陈永文. 共抑制分子PD-1的研究进展. 免疫学杂志, 2010, 26(7): 639-642.
|
12. |
Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol, 2009, 10(11): 1185-1192.
|
13. |
Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol, 2003, 33(10): 2706-2716.
|
14. |
Kataoka TR, Fujimoto M, Moriyoshi K, et al. PD-1 regulates the growth of human mastocytosis cells. Allergol Int, 2013, 62(1): 99-104.
|
15. |
Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol, 2002, 169(10): 5538-5545.
|
16. |
Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008, 26: 677-704.
|
17. |
Zhong X, Tumang JR, Gao W, et al. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol, 2007, 37(9): 2405-2410.
|
18. |
Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol, 2001, 22(4): 217-223.
|
19. |
Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl), 2003, 81(5): 281-287.
|
20. |
Guan X, Wang H, Ma F, et al. The efficacy and safety of programmed cell death 1 and programmed cell death 1 ligand inhibitors for advanced melanoma: a meta-analysis of clinical trials following the PRISMA guidelines. Medicine (Baltimore), 2016, 95(11): e3134.
|
21. |
Anthony B. PhaseⅠ/Ⅱ safety and antitumor activity of Nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol, 2015, 33(18_suppl): LBA101.
|
22. |
王征, 周俭. 中国肝癌肝移植现状及展望. 实用器官移植电子杂志, 2019, 7(1): 1-3.
|
23. |
李坚, 王洪林. 肝癌肝移植术后肝癌复发的研究进展. 中华外科杂志, 2005, 43(11): 753-756.
|
24. |
Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg, 2008, 143(2): 182-188.
|
25. |
Wang ZY, Geng L, Zheng SS. Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat Dis Int, 2015, 14(2): 145-149.
|
26. |
Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer, 2017, 64(12): e26682.
|
27. |
Varkaris A, Lewis DW, Nugent FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma. Am J Gastroenterol, 2017, 112(12): 1895-1896.
|
28. |
Rammohan A, Reddy MS, Farouk M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet? Hepatology, 2018, 67(3): 1166-1168.
|
29. |
De Toni EN, Gerbes AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient. Gastroenterology, 2017, 152(6): 1631-1633.
|
30. |
汪国营, 唐晖, 张英才, 等. 程序性死亡受体(PD)-1单克隆抗体治疗肝癌肝移植术后复发诱发急性免疫性肝炎: 附1例报告. 器官移植, 2016, 7(1): 44-47.
|
31. |
Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 Update. Liver Cancer, 2016, 6(1): 1-12.
|
32. |
Wanchoo R, Riella LV, Uppal NN, et al. Immune checkpoint inhibitors in the cancer patient with an organ transplant. J Onco Nephrol, 2017, 1: 42-48.
|
33. |
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol, 2007, 19(7): 813-824.
|
34. |
Riella LV, Paterson AM, Sharpe AH, et al. Role of the PD-1 pathway in the immune response. Am J Transplant, 2012, 12(10): 2575-2587.
|
35. |
Barnett R, Barta VS, Jhaveri KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med, 2017, 376(2): 191-192.
|